SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 110 filers reported holding SUTRO BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $261,291 | -21.7% | 75,300 | +4.9% | 0.00% | – |
| Q2 2023 | $333,917 | +40.6% | 71,810 | +39.7% | 0.00% | – |
| Q1 2023 | $237,468 | -42.8% | 51,400 | 0.0% | 0.00% | – |
| Q4 2022 | $415,312 | +55.5% | 51,400 | +6.9% | 0.00% | – |
| Q3 2022 | $267,000 | +58.9% | 48,100 | +48.9% | 0.00% | – |
| Q2 2022 | $168,000 | -90.1% | 32,300 | -84.3% | 0.00% | -100.0% |
| Q1 2022 | $1,693,000 | -47.2% | 205,924 | -4.5% | 0.00% | 0.0% |
| Q4 2021 | $3,208,000 | -17.0% | 215,566 | +5.3% | 0.00% | -50.0% |
| Q3 2021 | $3,866,000 | +88.4% | 204,677 | +85.5% | 0.00% | +100.0% |
| Q2 2021 | $2,052,000 | +1.5% | 110,357 | +24.2% | 0.00% | 0.0% |
| Q1 2021 | $2,022,000 | +486.1% | 88,824 | +458.6% | 0.00% | – |
| Q4 2020 | $345,000 | +167.4% | 15,900 | +24.2% | 0.00% | – |
| Q3 2020 | $129,000 | +30.3% | 12,800 | 0.0% | 0.00% | – |
| Q2 2020 | $99,000 | – | 12,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,675,579 | $13,773,000 | 3.47% |
| AJU IB Investment Co., Ltd. | 175,000 | $1,439,000 | 2.22% |
| Frazier Life Sciences Management, L.P. | 1,776,479 | $14,603,000 | 1.24% |
| First Light Asset Management, LLC | 1,672,497 | $13,748,000 | 1.21% |
| BVF INC/IL | 3,447,946 | $28,342,000 | 1.13% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,732,400 | $30,680,000 | 0.94% |
| Endurant Capital Management LP | 296,508 | $2,437,000 | 0.64% |
| Parkman Healthcare Partners LLC | 199,846 | $1,643,000 | 0.48% |
| Eventide Asset Management | 2,708,975 | $22,268,000 | 0.35% |
| Lombard Odier Asset Management (Switzerland) SA | 391,024 | $3,214,000 | 0.25% |